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Abstract
Background: Sphingoid bases are formed from the precursors L-serine and palmitoyl-CoA-a reaction which is
catalyzed by the serine-palmitoyltransferase (SPT). SPT metabolizes, besides palmitoyl-CoA also other acyl-CoAs but
shows also variability towards the use of other amino acid substrates. The enzyme is also able to metabolize
alanine, which results in the formation of an atypical deoxy-sphingoid base (DSB). This promiscuous activity is
greatly increased in the case of the sensory neuropathy HSAN1, and pathologically elevated DSB levels have been
identified as the cause of this disease. Clinically, HSAN1 shows a pronounced similarity to the diabetic sensory
neuropathy (DSN), which is the most common chronic complication of diabetes mellitus. Since serine and alanine
metabolism is functionally linked to carbohydrate metabolism by their precursors 3-phosphoglycerate and
pyruvate, we were interested to see whether the levels of certain sphingoid base metabolites are altered in
patients with diabetes.
Results: In a case-control study we compared plasma sphingoid base levels between healthy and diabetic
individuals. DSB levels were higher in the diabetic group whereas C16 and C18 sphingoid bases were not
significantly different. Plasma serine, but not alanine levels were lower in the diabetic group. A subsequent
lipoprotein fractionation showed that the DSBs are primarily present in the LDL and VLDL fraction.
Conclusion: Our results suggest that DSBs are a novel category of plasma biomarkers in diabetes which reflect
functional impairments of carbohydrate metabolism. Furthermore, elevated DSB levels as we see them in diabetic
patients might also contribute to the progression of the diabetic sensory neuropathy, the most frequent
complication of diabetes.
Introduction
Sphingolipids comprise a heterogeneous class of lipids
that contribute to plasma membrane and plasma lipopro-
tein formation. They are derived from the aliphatic
amino-alcohol sphingosine, which is commonly formed
from the precursors L-serine and palmitoyl-CoA. The
condensation of serine with palmitoyl-CoA is a pyridox-
alphosphate (PLP) dependent reaction and catalyzed by
the enzyme serine palmitoyltransferase (SPT) (EC
2.3.1.50). SPT is a heteromeric enzyme and composed of
at least three subunits (SPTLC1, SPTLC2 and SPTLC3)
[1,2]. The SPTLC2 and SPTLC3 subunits comprise a PLP
consensus sequence which is absent in the SPTLC1 subu-
nit. The product of the SPT reaction, 3-keto-sphinganine,
is converted to sphinganine (SA) and subsequently
N-conjugated with a second fatty acid to form dihydro-
ceramide (figure 1). The majority of dihydro-ceramide is
then desaturated at C4 to form ceramide, which is the
building block for the more complex sphingolipids. Cera-
mide and to a certain extent also dihydro-ceramide is
usually O-linked to a polar head group such as phospho-
choline or carbohydrates. This leads to a complex variety
of different sphingolipid metabolites. Although L-serine
and palmitoyl-CoA are the preferred substrates, the
enzyme shows a certain flexibility towards the use of
other substrates. Besides palmitoyl-CoA, SPT also meta-
bolizes other acyl-CoAs with a carbon chain length of
between C12 and C18. In this, the SPTLC3 subunit shows
a higher affinity towards shorter acyl-CoAs (e.g. C12
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and C14) whereas SPTLC2 shows a higher activity with
C16 and C18 acyl-CoAs. Both C18 sphingoid and C16
sphingoid bases have been detected in significant
amounts in human plasma [3].
Moreover, SPT shows variability towards the use of
other amino acid substrates. Besides L-serine, which is
the preferred substrate, the enzyme also metabolizes
L-alanine and to a certain extent glycine [4,5]. This gen-
erates an atypical category of sphingoid bases: the
1-deoxy-sphingoid bases (DSBs). The conjugation of ala-
nine forms deoxy-sphinganine (doxSA), whereas the use
of glycine results in the formation of deoxymethyl-
sphinganine (doxmethSA). Both metabolites are devoid
of the C1-hydroxyl group of SA and are therefore
neither metabolized to complex sphingolipids nor
degraded by the regular sphingolipid catabolism, since
sphingosine-1P as a catabolic intermediate cannot be
formed from DSBs.
The activity of SPT with alanine and glycine is greatly
increased in the presence of several SPT missense muta-
tions which are associated with the inherited sensory
neuropathy HSAN1 (OMIM162400). HSAN1 is an auto-
somal dominantly inherited axonal neuropathy that is
clinically characterized by a loss of pain and tempera-
ture sensation, usually starting in the lower limbs and
often accompanied by neuropathic pain attacks and skin
ulcers. The mutant SPT in HSAN1 shows a highly
increased activity with alanine and glycine compared to
the wildtype SPT. Consequently, these lipids are found
at elevated levels in cells and plasma from HSAN1
patients [4]. Significantly elevated DSB levels were also
found in plasma and PNS tissue of the HSAN1 mouse
model [6]. HSAN1 mice are transgenic for the mutant
SPT and develop a sensory neuropathy within 6-9
months of age. In contrast, double transgenic mice
which concomitantly co-express mutant and wildtype
SPT are protected and show, in parallel, also signifi-
cantly lower tissue and plasma DSB levels [6]. The addi-
tion of doxSA to DRGs resulted in a dose-dependent
reduction of neurite formation in-vitro and in a disrup-
tion of the neuronal cytoskeleton structure [4].
Originally, doxSA (also referred to as “Spisulosine” or
“ES-285”) has been isolated from the arctic clam Spisula
polynyma as an investigational marine anticancer drug.
It was shown to induce cell death in various breast can-
cer cell lines [7,8] and to interfere with stress fibre for-
mation and cytoskeleton dynamics by affecting Rho/
Rac-GTPase signaling cascades [9].
Clinically, HSAN1 shows a pronounced similarity to
the diabetic sensory neuropathy (DSN), which is the
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Figure 1 De-novo sphingolipid synthesis pathway. De-novo ceramide synthesis involves several steps. Serine Palmitoyltransferase (SPT)
catalyzes the initial conjugation of palmitoyl-CoA with L-serine to form 3-keto-sphinganine which is subsequently reduced to sphinganine (SA).
SA is acetylated by ceramide synthase (CerS) and desaturated by ceramide desaturase (DES) to form ceramide. The degradation pathway starts
with the deacetylation of ceramide by ceramidase. The sphingosine (SO) formed is then phosphorylated by SO-Kinase and finally degraded to
hexadecenal and phosphoethanolamine by the action of the sphingosine-1-phospate lyase (SO1P-lyase).
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most common chronic complication of diabetes mellitus.
Both diseases have a late onset and slow progression and
typically affect the distal extremities first. The degenera-
tion of small sensory fibers results in the loss of pain
sensation, which in turn leads to painless injuries [10].
In this context it is important to note that DSBs are
not exclusively formed by the mutant but also by the
wildtype SPT - however to a lesser extent [11]. Compar-
ing the kinetics between mutant and wildtype SPT
showed that both forms have similar Km’s for serine
and alanine but that Vmax for alanine is greatly
increased in the HSAN1 mutants [12]. Significant DSB
levels are therefore also detected in the plasma of
healthy individuals [4]. Interestingly, serine and alanine
metabolism is physiologically linked to the cellular
carbohydrate metabolism. Serine is formed from 3-
phosphoglycerate and alanine from pyruvate, which are
both intermediates of the glycolytic chain. Within this
framework of evidence, we were interested to investigate
whether sphingoid base levels are altered in patients
with an impaired glucose metabolism such as that seen
in diabetes mellitus.
Materials and methods
Patients
A total of 70 men and 29 women from Zurich volun-
teered to participate in the study. Written informed
consent was obtained from all participants and the local
Ethics Committees approved the study [13]. The case
group consisted of 50 consecutive Caucasian patients
with diagnosed diabetes mellitus type II. The control
group consisted of 49 Caucasians with no history of dia-
betes recruited from the general population. Clinical
chemistry analysis was carried out on a Roche-Hitachi
Modular Clinical Chemistry analyzer using commercial
tests from Roche Diagnostics (Rotkreuz, Switzerland).
Lipid extraction, hydrolysis and LC-MS analytic
Plasma sphingolipids were extracted and analyzed by
LC-MS as described earlier [4]
Separation of plasma lipoproteins
Plasma was isolated from diabetic donors after overnight
fasting. Three ml plasma was fractionated on a four step
density gradient essentially as described [14]. Ultracen-
trifugation was performed in a Beckman SW-40 swing-
ing bucket rotor for 24 h at 41000 rpm at 15°C.
Fractions (1 ml) were collected from the top of the cen-
trifuge tube and analyzed for triglyceride; cholesterol
and sphingoid bases were analyzed as described above.
Amino acid analysis
Plasma amino acid concentrations were analyzed
according to the method of Frank and Powers [15]
Statisics
Significance levels were determined with an unpaired
student t-test using Sigma Plot v10.0 (SystatSoftware,
Inc.). The correlation matrix was generated in SPSS
(SPSS, Switzerland). ROC analysis was performed with
XLSTAT (Addinsoft, Inc.)
Results
Sphingolipids in plasma are usually present in a broad var-
iation of subspecies. Sphingoid bases can be found in the
saturated (sphinganine, dihydro-sphingosine) and unsatu-
rated (sphingosine) state and are usually N-acetylated with
a second fatty acid. Most of the plasma sphingolipids are
also conjugated to O-linked head groups, which divert
them analytically into various subgroups. However, for
this study we were primarily interested in differences
between the individual sphingoid base backbones. We
therefore simplified the analysis by subjecting the sphingo-
lipids to a sequential acid and base hydrolysis. Acid hydro-
lysis specifically breaks the N-alkyl chain, whereas alkaline
conditions lead to a release of the O-linked head group.
The resulting free sphingoid base metabolites were ana-
lyzed by LC-MS. The sum of the individual sphingoid
bases reflects the total sphingolipid content in the
analyzed samples.
In this study we analyzed the C16-, C18-and deoxy-
sphingolipid levels in a case-control setup comparing 50
patients with documented diabetes mellitus type II (D)
and 49 healthy controls (C). The average age of the con-
trol group was slightly younger and included more
females than the diabetic group. Results are summarised
in table 1.
As reported earlier, the most abundant sphingoid
bases in plasma were C18-Sphingosine (C18SO) and
C16-Sphingosine (C16SO). The concentrations of
the dihydro-forms C18-Sphinganine (C18SA) and
C16-Sphinganine (C16SA) were much lower and repre-
sented about 1-5% of the respective sphingosine forms.
Deoxy-sphingoid bases were generally minor, represent-
ing 0.1-0.5% of the total plasma sphingoid bases. For the
DSBs the saturated (doxSA) and unsaturated (doxSO)
metabolites were found at similar concentrations. Deox-
ymethyl-SA or deoxymethyl-SO were not detected.
We found that the average doxSO levels were signifi-
cantly higher in the diabetic than in the control group.
Also doxSA levels were, although less pronounced,
higher in the diabetic group (table 1, figure 2A). On the
other hand, C16 and C18 sphingoid base levels were not
significantly different between the two groups. This indi-
cates that certain sphingoid bases are specifically altered
under diabetic conditions whereas others remain
unchanged. Among the other variables total-and
LDL-cholesterol was lower in the diabetic groups, which
is explained by the general administration of cholesterol
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lowering drugs (e.g. statins) in this group. HDL choles-
terol was lower in the diabetic groups whereas triglycer-
ides were not different. Age and smoking had no
influence.
Since doxSO showed the most significant changes
between the groups we calculated the diagnostic values
for this variable. A receiver operator curve (ROC) analy-
sis (figure 2B) revealed an area under the curve (AUC)
of 0.726. This converts into a sensitivity of 61% and a
specificity of 89% at a doxSO threshold of 0.2 μM. The
AUC for the other variables is summarized in figure 2C.
C16 and C18-sphingoid bases are functionally linked to
serine metabolism whereas the DSBs are linked to ala-
nine metabolism. We therefore also analyzed the plasma
amino acid levels between the two groups. Total amino
acid concentration was in general lower in diabetic
patients. The most significant changes were seen for
glycine, serine and threonine, whereas other amino acids
like alanine, valine or histidine were not altered (see
table 2).
The correlation matrix (table 3) for the individual
variables showed a strong correlation between the C16
and C18 sphingoid base metabolites. Also, doxSA and
doxSO correlated well with each other but less so with
the other sphingoid bases. For doxSO a weak but signifi-
cant correlation with C16 and C18SA was seen, but not
with the much more abundant C16 and C18SO. This
indicates that DSB generation is metabolically indepen-
dent from C16 and C18-sphingoid base formation. In
relation to other markers we observed a correlation of
the C16 and C18 sphingoid bases with total-as well as
HDL-and LDL-cholesterol. DSBs, in contrast, showed a
significant correlation with BMI and triglycerides (TG)
and to a certain extent with LDL, but not with HDL.
To gain further insight into the physiology of the
DSBs we analyzed their distribution into plasma lipo-
protein fractions. Lipoproteins were separated by ultra-
centrifugation, fractionated and the individual fractions
analyzed for cholesterol, triglycerides (TG) and
sphingoid bases (figure 2D). The C16-and the C18-
sphingolipids were found in the LDL and HDL but not
in the VLDL fraction. In contrast, the DSBs were pre-
dominantly found in LDL and VLDL but were nearly
absent in HDL. This indicates that the plasma DSBs
are of hepatic origin since LDL and VLDL but not
HDL primarily originate from the liver.
Discussion
In this study we demonstrate that deoxy-sphingoid bases
are elevated in patients with diabetes whereas the other
analysed sphingoid base metabolites like C16SA, C16SO,
C18SA and C18SO were not different. This indicates that
impairments in glucose metabolism as it is the base of dia-
betes are reflected in changes of some but not all sphin-
goid bases. Sphingolipid metabolism represents a
metabolic cross point which interconnects lipid (acyl-
CoA) and amino acid (serine and alanine) metabolism.
The cellular serine and alanine production is functionally
linked to carbohydrate metabolism by their precursors
3-phosphoglycerate and pyruvate and thereby indirectly
also to the carbohydrate metabolism. Therefore, the
observed changes indicate a functional interaction between
sphingolipid, glucose and fatty acid metabolism which
results in an increased production of DSBs in diabetes.
A limitation of this study is the overrepresentation of
patients receiving cholesterol lowering drugs in the dia-
betic group compared to the controls. Thus an impact
of statin treatment on the sphingoid base levels cannot
be completely excluded. However, diabetic patients with
and without statin treatment show no significant differ-
ences in the sphingoid base levels. This indicates that a
statin treatment does not significantly influence sphin-
goid base levels. Nevertheless, the influence of statins
needs to be addressed in more detail in further studies.
Overall plasma amino acid levels were found to be
lower in the diabetic group compared to controls.
Among the most significantly lowered amino acids were
threonine and serine. Plasma alanine levels, in contrast,
were not significantly different between the two groups.
It was recently shown that increasing L-alanine levels
stimulate DSB formation, whereas the presence of L-
serine suppresses DSB formation and increases the gen-
eration of C16 and C18 sphingoid bases [12]. The lower
Table 1 Baseline characteristics and sphingoid base
concentrations for the control and diabetic group
Control Diabetes P-value
N = 49 N = 50
AGE(y) 57.84 ± 11.64 63.31 ± 7.43 0.01
BMI 24.83 ± 4.00 28.97 ± 4.5 < 0.0001
Male (%) 54 84
CHOL (mM) 5.79 ± 1.26 4.82 ± 1.11 < 0.0001
HDL (mM) 1.64 ± 0.5 1.30 ± 0.33 < 0.0001
LDL (mM) 3.47 ± 0.97 2.90 ± 0.95 0.004
TG (mM) 1.48 ± 0.93 1.44 ± 0.67 0.77
CRP (mg/l) 2.01 ± 2.18 2.72 ± 4.14 0.28
SMOKING (%) 42 77
STATINS (%) 2 70
C16SO (μM) 11.06 ± 5.40 10.84 ± 8.71 0.88
C16SA (μM) 0.35 ± 0.18 0.30 ± 0.21 0.20
C18SO (μM) 79.44 ± 28.58 72.93 ± 38.76 0.34
C18SA (μM) 2.52 ± 0.91 2.22 ± 1.14 0.14
doxSO (μM) 0.12 ± 0.09 0.19 ± 0.15 0.005
doxSA (μM) 0.06 ± 0.04 0.08 ± 0.05 0.08
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Figure 2 A) Boxplot representation of C16, C18 and DSB levels in the control (C) and diabetic (D) cohort. Whereas C16SA, C16SO, C18SA
and C18SO were not different between the two groups were doxSA and doxSO levels higher in the diabetic group. (Box represents the upper
and lower quartile, whiskers show the 5% and 95% percentile, the horizontal line represents the median) C) Receiver operator curve (ROC) for
doxSO D) Area under the curve (AUC) and p-values for all analyzed variables were calculated from a ROC analysis. Most significant parameters
are marked (p values were calculated with the null hypothesis (H0) as AUC = 0.5). E) Distribution of the DSB and C16 sphingoid bases in the
distinct lipoprotein fractions. Human plasma was separated by a four step density gradient ultracentrifugation. The individual fractions were
assayed for cholesterol (not shown), triglycerides (TG; dashed line), doxSA (triangle) doxSO (triangle) and C16SO. Both doxSA and doxSO are only
found in the VLDL and LDL but not in the HDL lipoprotein fraction. C16-SO, in contrast, was present in LDL and HDL but not in VLDL. The sum
of all fractions was defined as 100% and values are given as a percentage of the total.
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serine levels in the diabetic group might therefore
explain why DSB levels were higher in the diabetics,
since the alanine to serine ratio was decreased in these
patients. However, lower levels of serine should then
also be associated with lower C18 and C18 sphingoid
base levels. This was, by trend, indeed the case although
the differences between the two groups were not signifi-
cant for this cohort.
Earlier reports on amino acid metabolism in obese
patients indicate that the situation might be more com-
plex, however. The observation that DSBs are preferen-
tially found in LDL indicates that the plasma DSB levels
are primarily of hepatic origin. It has been reported that
alanine uptake into the liver is significantly increased in
obese individuals [16]. Increased alanine uptake into the
liver might thus result in increased DSB formation.
However, due to the physiological alanine/glucose shut-
tle between muscle and liver, the hepatic uptake of ala-
nine is not necessarily reflected in generally lower
alanine levels in the venous blood [16].
Besides the direct uptake of alanine into the liver,
another mechanism might also contribute to increased
hepatic DSB generation. Hepatic glucose uptake is pri-
marily mediated by GLUT2 and is hence insulin inde-
pendent. Hyperglycemic conditions are therefore
associated with high hepatic glucose levels, leading to
increased glycolytic flux and production of pyruvate.
Hepatic glucose overload might therefore lead to a
build-up of pyruvate and its anaerobic conversion into
either lactate or alternatively alanine which, in turn, is
then converted to doxSA by the hepatic SPT.
This mechanism could also lead to increased DSB
generation in other tissues in which glucose uptake is
insulin independent, e.g. in kidney, pancreatic beta cells
or neurons.
Especially in peripheral neurons elevated DSB levels
could contribute to the pathology of diabetic sensory
neuropathy (DSN). The inherited neuropathy HSAN1 is
caused by a pathological overproduction of DSBs due to
several missense mutations in SPT [4]. Interestingly,
Table 2 Average plasma amino acid concentrations in the
control and diabetes group
Control Diabetes P-value
N = 49 N = 50
Glycine 412.88 ± 162.50 305.42 ± 92.80 0.0001
Alanine 408.91 ± 146.71 365.24 ± 126.73 0.12
Serine 151.83 ± 52.84 122.73 ± 34.64 0.001
Valine 646.17 ± 260.35 587.32 ± 186.66 0.20
Threonine 119.70 ± 44.43 86.99 ± 26.53 < 0.0001
Isoleucine 85.45 ± 37.29 69.30 ± 22.56 0.009
Leucine 153.52 ± 58.83 131.04 ± 44.77 0.03
Asparagine 119.13 ± 58.30 88.43 ± 33.58 0.002
Aspartate 25.84 ± 12.18 23.38 ± 11.56 0.30
Glutamine 339.60 ± 231.49 250.56 ± 160.35 0.02
Glutamate 325.21 ± 160.97 305.92 ± 120.57 0.50
Methionine 21.92 ± 68.40 22.84 ± 47.48 0.93
Histidine 167.69 ± 77.61 134.20 ± 46.86 0.02
Arginine 117.38 ± 47.40 110.61 ± 52.52 0.50
Tyrosine 81.49 ± 36.55 61.78 ± 24.87 0.002
Tryptophane 107.20 ± 36.72 86.90 ± 32.26 0.004
Sum 3283.91 ± 1137.04 2752.67 ± 692.84 0.0062
Values (μM) are given in mean +/- standard deviation.
Table 3 Correlation matrix of the analyzed variables
C16SO C16SA C18SO C18SA doxSO doxSA AGE BMI CHOL HDL LDL TG CRP
C16SO 0.43** 0.75** 0.36** 0.07 0.01 -0.12 -0.23* 0.22* 0.27** 0.18 -0.09 -0.10
C16SA 0.43** 0.57** 0.83** 0.27** 0.10 0.03 0.01 0.36** 0.20* 0.35** 0.13 -0.10
C18SO 0.75** 0.57** 0.65** 0.16 0.08 -0.06 -0.15 0.35** 0.36** 0.34** -0.10 -0.12
C18SA 0.36** 0.83** 0.65** 0.34** 0.21 0.09 0.05 0.49** 0.31** 0.48** 0.14 -0.03
doxSO 0.07 0.27** 0.16 0.34** 0.76** 0.05 0.32** 0.14 0.00 0.20* 0.29** 0.11
doxSA 0.01 0.10 0.08 0.21 0.76** 0.00 0.33** 0.23* 0.03 0.25* 0.27** 0.18
AGE -0.12 0.03 -0.06 0.09 0.05 0.00 0.12 -0.07 -0.05 -0.04 -0.06 0.12
BMI -0.23* 0.01 -0.15 0.05 0.32** 0.33** 0.12 -0.27* -0.45** -0.11 0.04 0.41**
CHOL 0.22* 0.36** 0.35** 0.49** 0.14 0.23* -0.07 -0.27* 0.49** 0.92** 0.44** -0.03
HDL 0.27** 0.20* 0.36** 0.31** 0.00 0.03 -0.05 -0.45** 0.49** 0.23* -0.14 -0.19
LDL 0.18 0.35** 0.34** 0.48** 0.20* 0.25* -0.11 -0.11 0.92** 0.23* 0.33** 0.03
TG -0.09 0.13 -0.10 0.14 0.29** 0.27** 0.04 0.04 0.44** -0.14 0.33** 0.08
CRP -0.10 -0.10 -0.12 -0.03 0.11 0.18 0.12 0.41** -0.03 -0.19 0.03 0.08
The pearson correlations were calculated for the whole dataset combining control and diabetic group. (Correlations ≥ 0.3 are highlighted bold, * p < 0.05, **p <
0.01)
Bertea et al. Lipids in Health and Disease 2010, 9:84
http://www.lipidworld.com/content/9/1/84
Page 6 of 7
HSAN1 and DSN are clinically very similar: both have a
late onset and slow progression and typically affect the
distal extremities first. All peripheral nerves are affected,
including pain fibers, motor neurons and autonomic
nerves. The degeneration of small sensory fibers results
in the loss of pain sensation, which in turn leads to
painless injuries. Both HSAN1 and DSN are associated
with skin ulcers, which is not a common feature in
other peripheral neuropathies. The pathological back-
ground of DSN is not yet fully understood. Several the-
ories have been discussed and might contribute to
unravelling the pathology of DSN. This includes micro-
angiopathy which results in neuronal ischemia, the for-
mation of advanced glycated end products (RAGE) due
to a non enzymatic glycosylation of proteins, chronic
PKC activation or the increased generation of sorbitol
via the polyol pathway, causing oxidative and osmotic
stress [17,18]. Considering the neurotoxic properties of
DSBs, it might therefore be conceivable that the elevated
DSB levels in diabetic patients also contribute to the
pathology of DSN.
However, in the context of our results, further studies
are necessary to validate the role of atypical sphingoid
bases as novel biomarkers in diabetes and to address a
potential involvement of these metabolites in the pathol-
ogy of DSN.
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